Department of Orthopedic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.
Oxid Med Cell Longev. 2020 Feb 1;2020:7540197. doi: 10.1155/2020/7540197. eCollection 2020.
As a joint disease, osteoarthritis (OA) is caused by the breakdown of subchondral bone and cartilage damage. Inflammatory factors, such as interleukin- (IL-) 1, mediate the progression of OA. Madecassoside (MA), a triterpenoid component derived from the gotu kola herb (), exhibits various pharmacological effects, including antioxidative and anti-inflammatory properties. In the present study, the protective effects and possible mechanism of MA on the treatment of OA were investigated. MA was demonstrated to significantly suppress the IL-1-induced overexpression of matrix metalloproteinase- (MMP-) 3, MMP-13, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) and to decrease the IL-1-induced degradation of type II collagen and sox9. Additionally, MA was able to reduce the IL-1-induced phosphorylation of p65 in osteoarthritic chondrocytes. Furthermore, in a rat OA model, MA prevented cartilage degeneration and reduced the OARSI score in the MA-treated group compared with the OA group. The present study showed that MA suppresses the nuclear factor-B signaling pathway, reducing IL-1-induced chondrocyte inflammation, which indicates the therapeutic potential of MA in patients with OA.
作为一种关节疾病，骨关节炎（OA）是由软骨下骨破坏和软骨损伤引起的。炎症因子如白细胞介素-（IL-）1 介导 OA 的进展。积雪草酸（MA）是一种从积雪草中提取的三萜类成分，具有多种药理作用，包括抗氧化和抗炎特性。本研究探讨了 MA 对 OA 治疗的保护作用及可能机制。结果表明，MA 可显著抑制 IL-1 诱导的基质金属蛋白酶-（MMP-）3、MMP-13、诱导型一氧化氮合酶（iNOS）和环氧化酶-2（COX-2）的过度表达，并减少 IL-1 诱导的 II 型胶原和 Sox9 的降解。此外，MA 还能减少 IL-1 诱导的 OA 软骨细胞中 p65 的磷酸化。此外，在大鼠 OA 模型中，与 OA 组相比，MA 治疗组可预防软骨退变并降低 OARSI 评分。本研究表明，MA 抑制核因子-B 信号通路，减少 IL-1 诱导的软骨细胞炎症，这表明 MA 在 OA 患者中的治疗潜力。
